Incubator escapee wiki

Rosuvastatin

Article Discussion
(Redirected from Crestor)

Template:Short description Template:Use dmy dates Template:Cs1 config Template:Main other <templatestyles src="Infobox drug/styles.css"/> {{#invoke:Infobox|infobox}}Template:Template other{{#invoke:TemplatePar |check |template=Template:Infobox_drug |all= |opt= pronounce= pronounce_ref= pronounce_comment= ATC_prefix= ATC_suffix= ATC_supplemental= ATCvet= biosimilars= CAS_number_Ref= CAS_number= CAS_supplemental= ChEBI= ChEBI_Ref= ChEMBL_Ref= ChEMBL= ChemSpiderID= ChemSpiderID_Ref= chirality= class= container_only= DailyMedID= data_page= DrugBank_Ref= DrugBank= Drugs.com= duration_of_action= INN= INN_EMA= IUPAC_name= IUPHAR_ligand= KEGG_Ref= KEGG= MedlinePlus= NIAID_ChemDB= PDB_ligand= PubChemSubstance= PubChem= StdInChIKey_Ref= StdInChIKey= StdInChI_Ref= StdInChI_comment= StdInChI= UNII_Ref= UNII= DTXSID= Verifiedfields= Watchedfields= addiction_liability= alt2= altL= altR= alt= bioavailability= boiling_high= boiling_notes= boiling_point= captionLR= caption= caption2= charge= chemical_formula= chemical_formula_ref= chemical_formula_comment= class1= class2= class3= class4= class5= class6= component1= component2= component3= component4= component5= component6= density= density_notes= dependency_liability= drug_name= elimination_half-life= engvar= excretion= image2= imageL= imageR= image= image_class= image_class2= image_classL= image_classR= Jmol= legal_AU= legal_BR= legal_CA= legal_DE= legal_EU= legal_NZ= legal_UK= legal_UN= legal_US= legal_AU_comment= legal_BR_comment= legal_CA_comment= legal_DE_comment= legal_UK_comment= legal_NZ_comment= legal_US_comment= legal_UN_comment= legal_EU_comment= legal_status= licence_CA= licence_EU= licence_US= license_CA= license_EU= license_US= mab_type= melting_high= melting_notes= melting_point= metabolism= metabolites= molecular_weight= molecular_weight_round= molecular_weight_unit= molecular_weight_ref= molecular_weight_comment= onset= pregnancy_AU= pregnancy_AU_comment= pregnancy_category= protein_bound= routes_of_administration= SMILES= smiles= solubility= sol_units= source= specific_rotation= synonyms= target= tradename= type= vaccine_type= verifiedrevid= width2= widthL= widthR= width= AAN= BAN= JAN= USAN= source_tissues= target_tissues= receptors= agonists= antagonists= precursor= biosynthesis= gt_target_gene= gt_vector= gt_nucleic_acid_type= gt_editing_method= gt_delivery_method= sec_combustion= Ac=Ag=Al=Am=Ar=As=At=Au=B=Ba=Be=Bh=Bi=Bk=Br=C=Ca=Cd=Ce=Cf=Cl=Cm=Cn=Co=Cr=Cs=Cu= D=Db=Ds=Dy=Er=Es=Eu=F=Fe=Fl=Fm=Fr=Ga=Gd=Ge=H=He=Hf=Hg=Ho=Hs=I=In=Ir=K=Kr=La=Li=Lr=Lu=Lv= Mc=Md=Mg=Mn=Mo=Mt=N=Na=Nb=Nd=Ne=Nh=Ni=No=Np=O=Og=Os=P=Pa=Pb=Pd=Pm=Po=Pr=Pt=Pu=Ra=Rb=Re=Rf=Rg=Rh=Rn=Ru=S=Sb=Sc=Se=Sg=Si=Sm=Sn=Sr=Ta=Tb=Tc=Te=Th=Ti=Tl=Tm=Ts=U=V=W=Xe=Y=Yb=Zn=Zr= index_label= index2_label= index_comment= index2_comment= CAS_number2= CAS_supplemental2= ATC_prefix2= ATC_suffix2= ATC_supplemental2= PubChem2= PubChemSubstance2= IUPHAR_ligand2= DrugBank2= ChemSpiderID2= UNII2= KEGG2= ChEBI2= ChEMBL2= PDB_ligand2= NIAID_ChemDB2= SMILES2= smiles2= StdInChI2= StdInChIKey2= CAS_number2_Ref= ChEBI2_Ref= ChEMBL2_Ref= ChemSpiderID2_Ref= DrugBank2_Ref= KEGG2_Ref= StdInChI2_Ref= StdInChIKey2_Ref= UNII2_Ref= DTXSID2= QID= QID2=PLLR= pregnancy_US= pregnancy_US_comment= |cat=Pages using infobox drug with unknown parameters |format=0|errNS=0

|preview=

@@@ (See parameter list). This message only shows in Preview, it will not show after you do Template:Button.

}}{{Infobox drug/maintenance categoriesTemplate:Yesno | drug_name = | INN = | _drugtype =

| _has_physiological_data= | _has_gene_therapy=

| vaccine_type= | mab_type= | _number_of_combo_chemicals={{#invoke:ParameterCount |main |component1 |component2 |component3 |component4|component5|component6 }} | _vaccine_data= | _mab_data= | _mab_vaccine_data= | _mab_other_data=2228136OC(=O)C[C@H](O)C[C@H](O)\C=C\c1c(C(C)C)nc(N(C)S(=O)(=O)C)nc1c2ccc(F)cc21S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1BPRHUIZQVSMCRT-VEUZHWNKSA-NTemplate:StdinchiciteTemplate:Stdinchicite | _combo_data= | _physiological_data= | _clinical_data=Template:Drugs.coma603033Rosuvastatin <ref name="Drugs.com pregnancy">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>DOral (by mouth)Crestor, othersC10Template:ATC, Template:ATC, Template:ATC, Template:ATC, Template:ATC, Template:ATC, Template:ATC, Template:ATC, Template:ATC, Template:ATC, Template:ATC, Template:ATC, Template:ATC | _legal_data=S4<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>Rx-only<ref name="Crestor SmPC">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>POM<ref name="Crestor FDA label" />Rx-onlyRx-only

| _other_data=(3R,5S,6E)-7-[4-(4-Fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid

| _image_0_or_2 = Rosuvastatin structure.svgRosuvastatin-3D-balls.png | _image_LR =

| _datapage = Rosuvastatin (data page) | _vaccine_target={{#ifeq: | vaccine | | _type_not_vaccine }} | _legal_all=S4Rx-onlyPOMRx-onlyRx-only | _ATC_prefix_supplemental=C10Template:ATC, Template:ATC, Template:ATC, Template:ATC, Template:ATC, Template:ATC, Template:ATC, Template:ATC, Template:ATC, Template:ATC, Template:ATC, Template:ATC, Template:ATC | _has_EMA_link = | CAS_number=287714-41-4 | PubChem=446157 | ChemSpiderID=393589 | ChEBI=38545 | ChEMBL=1496 | DrugBank=DB01098 | KEGG=D08492 | _hasInChI_or_Key={{#if:1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1BPRHUIZQVSMCRT-VEUZHWNKSA-N |yes}} | UNII=413KH5ZJ73 | _hasJmol02 = |_hasMultipleCASnumbers = 147098-20-2 |_hasMultiplePubChemCIDs = 5282455 |_hasMultipleChEBIs = 77249

| _countSecondIDs={{#invoke:ParameterCount |main |CAS_number2 |ATC_prefix2 |PubChem2 |PubChemStructure2 |IUPHAR_ligand2 |DrugBank2 |ChemSpiderID2 |UNII2 |KEGG2 |ChEBI2 |ChEMBL2 |PDB_ligand2 |NIAID_ChemDB2 |SMILES2 |smiles2 |StdInChI2 |StdInChIKey2 |DTXCID2}} | _countIndexlabels={{#invoke:ParameterCount |main |index_label |index2_label}} | _trackListSortletter= |QID = |QID2 = |Verifiedfields=changed |Watchedfields=changed |verifiedrevid=464383832}}

Rosuvastatin, sold under the brand name Crestor among others, is a statin medication, used to prevent cardiovascular disease in those at high risk and treat abnormal lipids.<ref name=AHFS2018/> It is recommended to be used with dietary changes, exercise, and weight loss.<ref name=AHFS2018/> It is taken orally (by mouth).<ref name=AHFS2018>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Common side effects include abdominal pain, nausea, headaches, and muscle pains.<ref name=AHFS2018/> Serious side effects may include rhabdomyolysis, liver problems, and diabetes.<ref name=AHFS2018/> Use during pregnancy may harm the baby.<ref name=AHFS2018/> Like all statins, rosuvastatin works by inhibiting HMG-CoA reductase, an enzyme found in the liver that plays a role in producing cholesterol.<ref name=AHFS2018/>

Rosuvastatin was patented in 1991 and approved for medical use in the United States in 2003.<ref name=AHFS2018/><ref name=Fis2006>Template:Cite book</ref> It is available as a generic medication.<ref name=AHFS2018/> In 2022, it was the thirteenth most commonly prescribed medication in the United States, with more than 37Template:Nbspmillion prescriptions.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> In Australia, it was one of the top 10 most prescribed medications between 2017 and 2023.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Medical usesEdit

File:Crestor Tablets (rosuvastatin).jpg
Rosuvastatin (marketed as Crestor) 10 mg tablets

The primary use of rosuvastatin is to prevent cardiovascular disease in those at high risk and to treat abnormal lipid levels in the blood.<ref name=AHFS2018/>

Effects on cholesterol levelsEdit

The effects of rosuvastatin on low-density lipoprotein (LDL) cholesterol are dose-related. Higher doses were more efficacious in improving the lipid profile of patients with hypercholesterolemia than milligram-equivalent doses of atorvastatin and milligram-equivalent or higher doses of simvastatin and pravastatin.<ref name="Jones-2003">Template:Cite journal</ref>

A meta-analysis showed that rosuvastatin can modestly increase the levels of high-density lipoprotein (HDL) cholesterol in the blood, similar to other statins.<ref name="pmid=18553127">Template:Cite journal</ref> A 2014 Cochrane review determined there was good evidence for rosuvastatin lowering non-HDL levels linearly with dose.<ref name="pmid25415541" />

Side effects and contraindicationsEdit

Side effects are uncommon:<ref name=MedLine>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

The following rare side effects are more serious. Like all statins, rosuvastatin can possibly cause myopathy, rhabdomyolysis:<ref name=MedLine/><ref name="Crestor FDA label" />

Allergic reactions can develop:<ref name="Crestor FDA label" />

Rosuvastatin has multiple contraindications, including hypersensitivity to rosuvastatin or any component of the formulation, active liver disease, elevation of serum transaminases, pregnancy, or breastfeeding.<ref name="Crestor FDA label">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Rosuvastatin is not prescribed nor used while pregnant, as it can cause serious harm to the fetus.<ref name="Crestor FDA label" /> With breastfeeding, it is unknown whether rosuvastatin is passed through breastmilk.<ref name="Crestor FDA label" /><ref name=LactMed>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

The risk of myopathy may be increased in Asian Americans: "Because Asians appear to process the drug differently, half the standard dose can have the same cholesterol-lowering benefit in those patients, though a full dose could increase the risk of side effects, a study by the drug's manufacturer, AstraZeneca, indicated."<ref>Template:Cite news</ref><ref>Template:Cite journal</ref><ref>Template:Cite journal</ref> Therefore, the lowest dose is recommended in Asians.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

MyopathyEdit

As with all statins, there is a concern of rhabdomyolysis, a severe undesired side effect. The U.S. Food and Drug Administration (FDA) has indicated that "it does not appear that the risk [of rhabdomyolysis] is greater with Crestor than with other marketed statins", but has mandated that a warning about this side-effect, as well as a kidney toxicity warning, be added to the product label.<ref name="FDAlabel">{{#invoke:citation/CS1|citation |CitationClass=web }} - This page is subject to change; the date reflects the last revision date.</ref><ref name="FDA Rosuvastatin Safety">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Diabetes mellitusEdit

Statins increase the risk of diabetes,<ref>Template:Cite journal</ref> consistent with FDA's review, which reported a 27% increase in investigator-reported diabetes mellitus in rosuvastatin-treated people.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Drug interactionsEdit

The following drugs can have negative interactions with rosuvastatin and should be discussed with the prescribing doctor:<ref name=MedLine/><ref name="Crestor FDA label" />

|CitationClass=web }}</ref>

Grapefruit juice negatively interacts with several specific drugs in the statin class, but it has little or no effect on rosuvastatin.<ref name="Bailey_2013">Template:Cite journal</ref>

StructureEdit

Rosuvastatin has structural similarities with most other statins, e.g., atorvastatin, cerivastatin and pitavastatin, but unlike other statins, rosuvastatin contains sulfur (in sulfonyl functional group). Crestor is a calcium salt of rosuvastatin, i.e., rosuvastatin calcium,<ref name="FDAlabel"/> in which calcium replaces the hydrogen in the carboxylic acid group on the right of the skeletal formula at the top right of this page.Template:Citation needed

Mechanism of actionEdit

Template:Further

Rosuvastatin is a competitive inhibitor of the enzyme HMG-CoA reductase, having a mechanism of action similar to that of other statins.<ref name="ASTEROID">Template:Cite journal</ref>

Putative beneficial effects of rosuvastatin therapy on chronic heart failure may be negated by increases in collagen turnover markers as well as a reduction in plasma coenzyme Q10 levels in patients with chronic heart failure.<ref>Template:Cite journal</ref>

PharmacodynamicsEdit

The dose-related magnitude of rosuvastatin on blood lipids was determined in a Cochrane systematic review in 2014. Over the dose range of 1 to 80 mg/day, strong linear dose‐related effects were found; total cholesterol was reduced by 22.1% to 44.8%, LDL cholesterol by 31.2% to 61.2%, non-HDL cholesterol by 28.9% to 56.7%, and triglycerides by 14.4% to 26.6%.<ref name="pmid25415541">Template:Cite journal</ref>

PharmacokineticsEdit

Absolute bioavailability of rosuvastatin is about 20% and Cmax is reached in 3 to 5 hours; administration with food did not affect the AUC according to the original sponsor submitted clinical study and as per product label.<ref name="Crestor FDA label" /> However, a subsequent clinical study has shown a marked reduction in rosuvastatin exposure when administered with food.<ref>Template:Cite journal</ref> It is 88% protein bound, mainly to albumin.<ref name=AHFS2018/> Fraction absorbed of rosuvastatin is frequently misquoted in the literature as approximately 0.5 (50%)<ref>Template:Cite journal</ref> due to a miscalculated hepatic extraction ratio in the original submission package subsequently corrected by the FDA reviewer.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Rosuvastatin is metabolized mainly by CYP2C9 and not extensively metabolized; approximately 10% is recovered as metabolite N-desmethyl rosuvastatin. It is excreted in feces (90%) primarily and the elimination half-life is approximately 19 hours.<ref name="Crestor FDA label" /><ref name=AHFS2018/>

Both AUC and Cmax are approximately 2-fold higher in Asian patients compared to Caucasian patients given the same dose of rosuvastatin.<ref name="Crestor FDA label" />

Society and cultureEdit

Rosuvastatin is the international nonproprietary name (INN).<ref name="INN">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

EconomicsEdit

Because low- to moderate dose statins are strongly recommended by the United States Preventive Services Task Force (USPSTF) for primary prevention of cardiovascular disease in adults aged 40–75 years who are at risk,<ref name=USPSTFstatins>Template:Cite journal</ref> the Patient Protection and Affordable Care Act (PPACA) in the United States requires most health insurance plans to cover the costs of these drugs without charging the insured patient a copayment or coinsurance, even if he or she has not yet reached his or her annual deductible.<ref name="AZHR">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref name="HealthcareDotGovPreventiveCare">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref name="KFFACApreventive">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Rosuvastatin 5 mg and 10 mg are examples of regimens meeting the USPSTF guideline;<ref name=USPSTFstatins/> however, insurers have discretion as to which low- and moderate-dose statin regimens to cover under this requirement,<ref name=ACApreventiveFAQ>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> and some only cover other statins.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

The drug was billed as a "super-statin" during its clinical development; the claim was that it offered high potency and improved cholesterol reduction compared to rivals in the class. The main competitors to rosuvastatin are atorvastatin and simvastatin. However, people can also combine ezetimibe with either simvastatin or atorvastatin and other agents on their own, for somewhat similar augmented response rates. Template:As of some published information for comparing rosuvastatin, atorvastatin, and ezetimibe/simvastatin results are available, but many of the relevant studies are stillTemplate:When in progress.<ref name="ASTEROID"/>Template:Update inline

First launched in 2003, sales of rosuvastatin were $129Template:Nbspmillion and $908Template:Nbspmillion in 2003, and 2004, respectively, with a total patient treatment population of over 4Template:Nbspmillion by the end of 2004.Template:Citation needed Annual cost to the UK National Health Service (NHS) in 2018, for 5–40 mg rosuvastatin daily (of one person) was £24-40, compared to £10-20 for 20–80 mg simvastatin.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

In 2013, it was the fourth-highest-selling drug in the United States, accounting for approximately $5.2Template:Nbspbillion in sales.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> In 2021, it was the thirteenth most commonly prescribed medication in the United States, with more than 32Template:Nbspmillion prescriptions.<ref name="Rosuvastatin - Drug Usage Statistics">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Legal statusEdit

Rosuvastatin is approved in the United States for the treatment of high LDL cholesterol (dyslipidemia), total cholesterol (hypercholesterolemia), and/or triglycerides (hypertriglyceridemia).<ref name="pill">{{#invoke:citation/CS1|citation |CitationClass=web }} - NOTE: this is provider-oriented information and should not be used without the supervision of a physician.</ref> In February 2010, rosuvastatin was approved by the FDA for the primary prevention of cardiovascular events.<ref name="fdaap">Template:Cite report</ref>

Template:As of, rosuvastatin had been approved in 154 countries and launched in 56. Approval in the United States by the Food and Drug Administration (FDA) came on 13 August 2003.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref name="FDAapproval">Template:Cite news</ref>

Patent protection and generic versionsEdit

The main patent that protected rosuvastatin (RE37,314, which expired in 2016) was challenged as an improper reissue of an earlier patent. This challenge was rejected in 2010, and thus, patent protection continued until 2016.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}Template:Dead link</ref><ref>Template:Cite press release</ref><ref>Template:Cite news</ref><ref>Template:Cite news Template:Subscription required</ref><ref>Template:Cite press release</ref>

In April 2016, the FDA approved the first generic version of rosuvastatin (from Watson Pharmaceuticals Inc).<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> In July 2016, Mylan gained approval for its generic rosuvastatin calcium.<ref>Template:Cite press release</ref>

Debate and criticismsEdit

In October 2003, several months after its introduction in Europe, Richard Horton, the editor of the medical journal The Lancet, criticized the way Crestor had been introduced. "AstraZeneca's tactics in marketing its cholesterol-lowering drug, rosuvastatin, raise disturbing questions about how drugs enter clinical practice and what measures exist to protect patients from inadequately investigated medicines," according to his editorial. The Lancet's editorial position is that the data for Crestor's superiority rely too much on extrapolation from the lipid profile data (surrogate end-points) and too little on hard clinical end-points, which are available for other statins that had been on the market longer. The manufacturer responded by stating that few drugs had been tested so successfully on so many patients. In correspondence published in The Lancet, AstraZeneca's CEO Tom McKillop called the editorial "flawed and incorrect" and slammed the journal for making "such an outrageous critique of a serious, well-studied medicine."<ref name="lancetoped">Template:Cite journal
Template:Cite journal</ref>

In 2004, the consumer interest organization Public Citizen filed a Citizen's Petition with the FDA, asking that Crestor be withdrawn from the US market. On 11 March 2005, the FDA issued a letter to Sidney M. Wolfe of Public Citizen both denying the petition and providing an extensive detailed analysis of findings that demonstrated no basis for concerns about rosuvastatin compared with the other statins approved for marketing in the United States.<ref name="FDA ruling">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> In 2015, Wolfe explained why he thought that "the drug should have been withdrawn and why it should not be used", due to the incidence of rhabdomyolysis, renal problems, and significant increase in glycated hemoglobin (HbA1C) and fasting insulin levels, and decreased insulin sensitivity in diabetic patients. Rosuvastatin indeed lowered cholesterol more than other statins, but Wolfe asked, "what about actually improving health, preventing heart attacks and strokes?"<ref name=wolfe>Template:Cite journal</ref>

ReferencesEdit

Template:Reflist

Template:Statins Template:AstraZeneca Template:Portal bar Template:Authority control

Retrieved from "https://zalansite.site/mediawiki/index.php?title=Rosuvastatin&oldid=383655"